Eli Lilly & Co. (NYSE:LLY)

A significant valuation cycle is evident across all measured ratios, characterized by a period of aggressive expansion peaking in the fourth quarter of 2023, followed by a sustained correction and normalization phase through the first half of 2026.

Price to Earnings (P/E) Ratio

The P/E ratio experienced a steep ascent from 45.29 in March 2022 to a peak of 135.24 in December 2023. This peak was followed by a consistent downward trend throughout 2024 and early 2025, reaching a low of 34.82 in March 2026. The ratio ended the period at 41.23, returning to levels comparable to the start of the analysis period.

Price to Operating Profit (P/OP) Ratio

Mirroring the P/E trend, the P/OP ratio rose from 36.49 in March 2022 to a maximum of 109.75 in December 2023. A subsequent contraction led the ratio to its lowest point of 27.92 in March 2026, before a slight recovery to 32.74 by June 2026. This suggests a significant realignment of the share price relative to operating performance.

Price to Sales (P/S) Ratio

The P/S ratio climbed from 9.47 in March 2022 and peaked at 20.77 in December 2023. Valuation remained elevated throughout the first half of 2024 before declining to 11.39 in June 2025. The ratio showed modest volatility in the final quarters, ending at 13.82 in June 2026.

Price to Book Value (P/BV) Ratio

The P/BV ratio increased from 29.75 in March 2022 to a peak of 65.80 in December 2023. Following this peak, the ratio remained relatively high through 2024 before dropping sharply to 33.19 in June 2025. The period concluded with the ratio at 32.51 in June 2026, indicating a return to baseline valuation levels relative to equity.

The synchronized peaking of all four valuation metrics in December 2023 indicates a period of extreme market optimism. The subsequent decline across all metrics suggests that growth in earnings, operating profit, sales, and book value eventually outpaced the growth in share price, leading to a more conservative valuation by mid-2026.

The financial data reveals a distinct three-phase cycle characterized by initial valuation expansion, a period of extreme premium pricing, and a subsequent normalization driven by significant earnings growth.

Valuation Expansion Phase

Between March 2022 and December 2023, the price-to-earnings (P/E) ratio exhibited a sharp upward trajectory, rising from 45.29 to a peak of 135.24. During this interval, the share price increased from 292.13 to 745.91, while earnings per share remained relatively stagnant, fluctuating between 5.25 and 6.84. This divergence indicates a period where market valuation was driven by anticipated future growth rather than realized current earnings.

Earnings Acceleration Phase

Starting in mid-2024, a fundamental shift occurred as earnings per share began to grow rapidly. EPS climbed from 7.73 in June 2024 to 28.38 by June 2026. Although the share price continued its general ascent, peaking at 1,169.86, the rate of earnings growth significantly outpaced the rate of price appreciation during this window.

Valuation Compression and Normalization

As a direct result of the earnings surge, the P/E ratio entered a sustained period of contraction. From the peak of 135.24 in December 2023, the ratio declined steadily to a low of 34.82 by March 2026. This compression demonstrates a transition from a speculative valuation model to one supported by fundamental profitability, with the P/E ratio ultimately stabilizing at 41.23 by June 2026.

The Price to Operating Profit (P/OP) ratio exhibits a pronounced cyclical pattern over the analyzed period, characterized by a period of aggressive valuation expansion followed by a significant normalization as operating profitability increased.

Valuation Expansion Phase (March 2022 – December 2023)

A sharp increase in the P/OP ratio is observed, rising from 36.49 to a peak of 109.75. This trend was driven by a substantial increase in the share price, which climbed from 292.13 to 745.91, while operating profit per share remained relatively stagnant or declined slightly, moving from 8.01 to 6.80. This divergence indicates that market valuation significantly outpaced actual operating performance during this interval.

Normalization and Convergence Phase (March 2024 – June 2025)

A consistent downward trend in the P/OP ratio occurs, falling from 99.34 to 35.19. This contraction is attributed to a rapid acceleration in operating profit per share, which grew from 7.86 to 18.21. Although the share price reached new heights during the first half of 2024, the rate of growth in operating profits surpassed the rate of share price appreciation, effectively lowering the valuation multiple.

Fundamental Stability Phase (September 2025 – June 2026)

The P/OP ratio enters a period of relative stability, fluctuating between a low of 27.92 and a high of 37.24. This stability is supported by continued strong growth in operating profit per share, which reached 35.73 by June 2026. The alignment of the P/OP ratio with levels seen at the start of the data series suggests that the valuation has returned to a baseline more closely correlated with the company's fundamental operating earnings.

In summary, the data reflects a transition from a speculative valuation peak to a profit-supported valuation. The significant rise in operating profit per share toward the end of the period served as the primary catalyst for the compression of the P/OP ratio, moving the stock from an era of extreme premium to one of fundamental alignment.

The Price-to-Sales (P/S) ratio exhibits a period of aggressive expansion followed by a corrective phase and subsequent stabilization. Between March 2022 and December 2023, the valuation multiple more than doubled, peaking at 20.77. This movement indicates a period where share price appreciation significantly outpaced the growth in sales per share, suggesting that market expectations for future growth were priced in well ahead of actual revenue realization.

Share Price Trajectory

The share price demonstrates a strong overall upward trend, increasing from 292.13 in March 2022 to 1,169.86 by June 2026. Although the long-term trend is positive, a significant volatility window is observed between December 2024 and June 2025, during which the price declined from 867.05 to 640.86 before entering a second phase of rapid appreciation.

Sales per Share Growth

Revenue performance per share remained relatively flat throughout 2022, hovering around 30.00 to 30.86. A transition to accelerated growth began in March 2023, with sales per share rising consistently every quarter to reach 84.63 by June 2026. This represents a nearly threefold increase in sales per share over the analyzed period, reflecting strong fundamental growth.

Valuation Ratio Correlation

The P/S ratio dynamics reveal a decoupling and subsequent realignment of price and revenue. From March 2022 to December 2023, the ratio rose from 9.47 to 20.77 as price growth eclipsed revenue growth. From January 2024 to June 2025, the ratio compressed to 11.39, as the acceleration in sales per share effectively "caught up" to the valuation. In the final year of the sequence, the ratio fluctuated between 12.18 and 15.03, suggesting a stabilization of the valuation multiple relative to the company's increased revenue base.

The valuation of the equity shows a distinct cycle of rapid expansion followed by a period of correction and normalization. While both the market price and the book value per share exhibited long-term growth, the divergence between these two metrics created significant volatility in the price-to-book value (P/BV) ratio, which peaked in late 2023 before retreating toward historical baselines by mid-2026.

Share Price Evolution

A strong upward trajectory is observed, with the share price increasing from 292.13 USD in March 2022 to a peak of 1,169.86 USD by June 2026. The most aggressive growth occurred between March 2023 and December 2023, where the price rose from 390.35 USD to 745.91 USD. A temporary correction occurred in the first half of 2025, with a dip to 640.86 USD in June 2025, prior to a subsequent recovery.

Book Value per Share (BVPS) Progression

The book value per share maintained a steady, incremental rise for the majority of the period, moving from 9.82 USD in March 2022 to 14.97 USD by December 2024. A notable acceleration in BVPS growth is evident starting in March 2025, with the value increasing from 16.63 USD to 35.99 USD by June 2026, representing a significant strengthening of the company's net asset base per share in the final quarters of the analysis.

P/BV Ratio Analysis

The P/BV ratio experienced three distinct phases. Initially, from March 2022 to December 2022, the ratio remained relatively stable between 29.36 and 34.00. A phase of extreme valuation expansion followed, peaking at 65.80 in December 2023, driven by share price gains that vastly outpaced the growth in book value. In the final phase, starting in March 2025, the ratio contracted sharply to a low of 28.21 in March 2026, resulting from a combination of share price volatility and the accelerated growth of the book value per share.

Overall, the data indicates that the market valuation premium reached an unsustainable peak in 2023 and 2024. The subsequent decline in the P/BV ratio toward the 32.51 level seen in June 2026 suggests a realignment where the market price is more closely supported by the underlying book value of the company.